Wedbush Reiterates Outperform on Telix Pharmaceuticals, Maintains $22 Price Target
Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price target.
Read original at benzingaStocks · News reference
Telix Pharmaceuticals Announces That The First Patient Has Been Dosed With TLX250-Tx In The LUTEON Study
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announced that the first patient has been dosed with TLX250-Tx (lutetium-177 (177Lu) girentuximab tetraxetan) in the LUTEON study, the first
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 9:14 PM
- Checked
- Jul 20, 2026, 9:14 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Reported Earlier, Telix Pharmaceuticals Guides FY 2026 Revenue Of $950M-$970M, Total Income Above $1B, Reaffirms R&D Guidance Of $230M-$270M
Read original at benzingaReported Earlier, Telix Pharmaceuticals Reports H1 2026 Revenue Of $477M, Up 22% YoY, And Profit After Tax Of $38M Versus $2M Loss
Read original at benzingaTelix H1 2026 Results: Investor Webcast Notification
Telix Pharmaceuticals announced it will release its half-year financial results for June 30, 2026 on August 20, 2026, with an accompanying investor webcast and conference call. The company reported Q2 2026 revenue of US$247M with strong commercial momentum and pipeline progress across its radiopharmaceutical portfolio.
Read original at globenewswire-inc